MicroQuin is a biotechnology company focused on a novel and broadly impactful target, MicroQuin created smarter therapeutics to address the world’s most challenging diseases, with initial focus on cancer. MicroQuin was a 2018 MassChallenge Finalist (premier global accelerator) and winner of the CASIS/Boeing Prize to fund research on the International Space Station. The company is currently headquartered at the prestigious LabCentral in Kendall Square, Cambridge, MA.
Scott Robinson, PhD
Dr. Scott Robinson holds a Ph.D. from Imperial College London where he specialized in cell stress signaling and cell death/survival pathways. Previously he worked for GlaxoSmithKline investigating drug candidates through proteomic analysis and target-based drug discovery techniques. Within academia Dr. Robinson has published numerous papers in world-leading scientific journals, including Nature. At MicroQuin, Dr. Robinson drives the company vision and leads all scientific efforts to drive its assets through scientific advancement, collaborative efforts and licensing agreements. Recently, he secured $750K funding from the Center for Advancement of Science in Space (CASIS) to develop MicroQuin technology on the International Space Station. Furthermore, Dr. Robinson has 8 years of Investment Banking experience in Risk Management and Quantitative Financial Modelling at Morgan Stanley and Nomura.